TIFA, an inflammatory signaling adaptor, is tumor suppressive for liver cancer

Oncogenesis

Volumn 4, Issue 10, 2015, Pages

  Shen, W ^a   Chang, A ^a   Wang, J ^a   Zhou, W ^a   Gao, R ^a   Li, J ^a   Xu, Y ^a   Luo, X ^a   Xiang, R ^a   Luo, N ^a   Stupack, D G ^b  

^a NANKAI UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; PROTEIN P53; TNF RECEPTOR ASSOCIATED FACTOR INTERACTING PROTEIN WITH A FORKHEAD ASSOCIATED DOMAIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER BIOPSY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UBIQUITINATION;

EID: 84989339637     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2015.30     Document Type: Article

References (28)

1. Zhang C, Bai N, Chang A, Zhang Z, Yin J, Shen W et al. ATF4 is directly recruited by TLR4 signaling and positively regulates TLR4-trigged cytokine production in human monocytes. Cell Mol Immunol 2013; 10: 84-94.
2. Zhang Z, Yin J, Zhang C, Liang N, Bai N, Chang A et al. Activating transcription factor 4 increases chemotherapeutics resistance of human hepatocellular carcinoma. Cancer Biol Ther 2012; 13: 435-442.
3. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.
4. Wang L, Zhu R, Huang Z, Li H, Zhu H. Lipopolysaccharide-induced Toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma. Dig Dis Sci 2013; 58: 2223-2236.
5. Duan M, Wang ZC, Wang XY, Shi JY, Yang LX, Ding ZB et al. TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression. Ann Surg Oncol 2014; 22: 3121-3129.
6. Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res 2012; 72: 3977-3986.
7. Ding N, Zhang Y, Loughran PA, Wang Q, Tsung A, Billiar TR. TIFA upregulation after hypoxia-reoxygenation is TLR4-And MyD88-dependent and associated with HMGB1 upregulation and release. Free Radic Biol Med 2013; 63: 361-367.
8. Takatsuna H, Kato H, Gohda J, Akiyama T, Moriya A, Okamoto Y et al. Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-Associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-Associated kinase-1 (IRAK-1) in IL-1 receptor signaling. J Biol Chem 2003; 278: 12144-12150.
9. Kanamori M, Suzuki H, Saito R, Muramatsu M, Hayashizaki Y. T2BP, a novel TRAF2 binding protein, can activate NF-kappaB and AP-1 without TNF stimulation. Biochem Biophys Res Commun 2002; 290: 1108-1113.
10. Li J, Lee GI, Van Doren SR, Walker JC. The FHA domain mediates phosphoprotein interactions. J Cell Sci 2000; 113(): 4143-4149.
11. Huang CC, Weng JH, Wei TY, Wu PY, Hsu PH, Chen YH et al. Intermolecular binding between TIFA-FHA and TIFA-pT mediates tumor necrosis factor alpha stimulation and NF-kappaB activation. Mol Cell Biol 2012; 32: 2664-2673.
12. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002; 418: 443-447.
13. Ea CK, Sun L, Inoue J, Chen ZJ. TIFA activates IkappaB kinase (IKK) by promoting oligomerization and ubiquitination of TRAF6. Proc Natl Acad Sci USA 2004; 101: 15318-15323.
14. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013; 32: 5129-5143.
15. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28: 3994-4005.
16. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
17. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
18. Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr Pharm Design 2007; 13: 367-385.
19. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
20. Krakauer T. Caspase inhibitors attenuate superantigen-induced inflammatory cytokines, chemokines, and T-cell proliferation. Clin Diagn Lab Immunol 2004; 11: 621-624.
21. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M et al. Clinical trial of the Pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007; 7: 218-225.
22. Iwata A, Harlan JM, Vedder NB, Winn RK. The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials. Blood 2002; 100: 2077-2080.
23. Arthur JS, Ley SC. Mitogen-Activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13: 679-692.
24. Cuevas BD, Abell AN, Johnson GL. Role of mitogen-Activated protein kinase kinase kinases in signal integration. Oncogene 2007; 26: 3159-3171.
25. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.
26. Huang G, Shi LZ, Chi H. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. Cytokine 2009; 48: 161-169.
27. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100-3112.
28. Tanoue T, Nishida E. Molecular recognitions in the MAP kinase cascades. Cell Signal 2003; 15: 455-462.